Karin Ludwig
Keine laufenden Positionen mehr
Profil
Dr. Karin Ludwig, MD, is Vice President-Clinical Development at Acucela, Inc.
Dr. Ludwig was previously employed as Chief Medical Officer by Alacrity Biosciences, Inc., Senior Director by Pfizer Inc., and Senior Vice President-Clinical Research by Amicus Therapeutics, Inc.
She received her doctorate degree from the University of Freiburg.
Ehemalige bekannte Positionen von Karin Ludwig
| Unternehmen | Position | Ende |
|---|---|---|
| ACUCELA INC | Corporate Officer/Principal | - |
| AMICUS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Alacrity Biosciences, Inc.
 Alacrity Biosciences, Inc. Medical DistributorsDistribution Services Alacrity Biosciences, Inc. develops and markets pharmaceutical products, which are used in ophthalmology. The company was founded on November 9, 2006 and is headquartered in New York, NY. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Karin Ludwig
| University of Freiburg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Alacrity Biosciences, Inc.
Alacrity Biosciences, Inc. Medical DistributorsDistribution Services Alacrity Biosciences, Inc. develops and markets pharmaceutical products, which are used in ophthalmology. The company was founded on November 9, 2006 and is headquartered in New York, NY. | Distribution Services |
Acucela, Inc.
 Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
